On December 4, 2025 Caris Life Sciences (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, reported that the company and collaborators from leading cancer centers, including those within the Caris Precision Oncology Alliance (Caris POA), will collectively present 19 studies across a range of breast cancer types at the San Antonio Breast Cancer Symposium (SABCS) from December 9-12, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The studies investigated seven distinct breast cancer subtypes, including HR+/HER2–, HER2-positive, HER2-low/ultralow/null, triple-negative, invasive lobular carcinoma, male and metastatic. The range of studies demonstrates how multi-omics-driven profiling, subtyping and biomarker discovery accelerate precision oncology and improve patient outcomes. The studies represent 40+ collaborating institutions, including leading NCI-designated cancer centers.

"SABCS is the premier global stage for advancing breast cancer research, and we are excited to share how Caris’ multi-omic tumor profiling is helping define molecularly distinct patient groups," said George W. Sledge, Jr., MD, Caris EVP and Chief Medical Officer. "By integrating whole exome and whole transcriptome sequencing with IHC profiling and AI-driven signatures, we are uncovering new insights into therapeutic resistance and real-world outcomes that bring us closer to truly personalized cancer care."

"The selection of two studies we collaborated on for oral and rapid oral presentations underscores Caris’ leadership in multimodal AI for recurrence prediction and risk stratification in early and late breast cancer," said Caris President David Spetzler, MS, PhD, MBA.

Oral Presentation:

Multimodal Artificial Intelligence (AI) Models Integrating Image, Clinical, and Molecular Data for Predicting Early and Late Breast Cancer Recurrence in TAILORx. Oral #GS1-09
General Session 1. December 10, 2025. 11:30 AM-11:45 AM CST
Rapid Oral Presentation:

A Multimodal-Multitask Deep Learning Model Trained in NSABP B-42 and Validated in TAILORx for Late Distant Recurrence Risk in HR+ Early Breast Cancer. Rapid Oral #RF3-07
Rapid Fire 3. December 10, 2025. 5:18-5:26 PM CST
Spotlight Posters Include:

Personalized Acquired CDK4/6i Resistance: Associations with Baseline Characteristics Like Obesity in Real-World (RW) Clinical-Multiomics Data. #PD3-02
Poster Spotlight 3. December 10, 2025. 7:33-7:36 AM CST
Overcoming ADC Resistance: Payload Diversification as a Strategy for Sequential Therapy.
#PD3-11
Poster Spotlight 3. December 10, 2025. 8:12-8:15 AM CST
The Genomic, Transcriptomic, and Immune characterization of Metastatic Lobular Breast Cancer. #PD9-07
Poster Spotlight 9. December 11, 2025. 8:00-8:03 AM CST
Differential Benefit to Elacestrant in a Large Cohort of ER+ Breast Cancer: Impact of ESR1 mutants and prior therapy. #PD10-11
Poster Spotlight 10. December 12, 2025. 8:12-8:15 AM CST
Posters Include:

Outcomes in patients with PIK3CA-mutated breast cancer treated with metformin. #PS1-11-11
Poster Session 1. December 10, 2025. 12:30-2:00 PM CST
Evaluation of steroid hormone receptor expression and clinical outcomes in ER-positive breast cancer bone metastases. #PS1-11-27
Poster Session 1. December 10, 2025. 12:30-2:00 PM CST
Comprehensive Characterization of PTEN loss by IHC and PTEN alteration by NGS in Metastatic HR-Positive, HER2-Negative Breast Cancer– An Exploratory Analysis of Biomarker Concordance and Co-Occurrence. #PS2-08-02
Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
Site specific Genomic and Immune Landscapes Underpinning in metastatic Male Breast Cancer. #PS2-08-04
Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
Chemokine signatures improve PD-L1-based prediction of pembrolizumab response in triple-negative breast cancer. #PS2-08-14
Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
Tertiary lymphoid structure (TLS)-related gene expression and outcomes in HER2-Positive (HER2+) breast cancer (BC) in the Real-World Database. #PS2-09-08
Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
TONSL, an immortalizing oncogene on Chr.8q24.3 amplicon, confers intrinsic resistance to CDK4/6 inhibitors in breast cancer. #PS2-09-19
Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
Combined T and B Cell Signatures as Prognostic Biomarkers in Triple-Negative Breast Cancer (TNBC). #PS2-10-25
Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
Metabolic and Immune Reprogramming via SCD1 Inhibition Enhances Chemo-Immunotherapy Response in TNBC. #PS2-12-07
Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
Immune microenvironment and survival differences among Hispanic and African American breast cancer cases by biopsy site. #PS3-12-06
Poster Session 3. December 11, 2025. 12:30-2:00 PM CST
Comparative efficacy of antibody drug conjugates (ADCs) in male versus female breast cancer across the spectrum of HER2 expression. #PS4-01-13
Poster Session 4. December 11, 2025. 5:00 – 6:30 PM CST
Evaluation of Metabolic Dysregulation, Endocrine Therapy Outcomes, and Tumor Biology in HER2-/HR+ Breast Cancer using a Multi-Omic, Real-World Analysis. #PS4-01-14
Poster Session 4. December 11, 2025. 5:00 – 6:30 PM CST
EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition. #PS4-05-05
Poster Session 4. December 11, 2025. 5:00 – 6:30 PM CST
Poster and abstract summaries highlighting this research will be available onsite at Caris’ booth #209. The full abstracts will be available on the Caris website following the presentations.

The Caris Precision Oncology Alliance consists of 98 cancer centers, academic institutions, research consortia and healthcare systems, including 45 NCI-designated cancer centers, all collaborating to advance precision oncology and biomarker-driven research. Caris and Caris POA members collaborate to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers, aiming to improve clinical outcomes for cancer patients.

(Press release, Caris Life Sciences, DEC 4, 2025, View Source [SID1234661136])